Javier Coindreau, M.D.

SVP, Medical Affairs

Javier Coindreau, M.D., is an internist and rheumatologist, as well as a medical affairs leader with a 24-year career across multiple therapeutic areas, focusing on autoimmune diseases, chronic inflammatory conditions, and rare diseases. He has held leadership roles in global and US organizations within several pharmaceutical and biotech companies. Passionate about developing people and building efficient, productive medical teams, he successfully built and led the Pfizer Biosimilar Global Medical Affairs team, Gilead Inflammation Global and US Medical Teams, and the Aurinia US team. Dr. Coindreau has launched eight drugs globally and more than 20 new indications and label expansions, leading Phase 3b development programs and various lifecycle management research projects in lupus, rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, chronic tophaceous gout, Crohn's disease, and others. His medical affairs and development responsibilities encompass multiple biologic compounds, small molecules, biosimilars, targeted therapies, gene therapy (including DNA editing and CRISPR), and cell therapy for Type 1 diabetes and sickle cell disease. He has also led medical integration efforts during mergers, including the Hospira and Pfizer global integration and the Galapagos and Gilead medical functional integration, while assessing various acquisition and licensing opportunities. In addition to his industry experience, Dr. Coindreau held a position as an associate professor of Medical Affairs at King's College, collaborates with the Education Team of the Medical Affairs Professional Society, and possesses extensive patient care experience in rheumatology. He is also a certified executive coach.